Vyriad has developed and validated an antibody test to measure antibodies capable of blocking infection by SARS-CoV-2, the novel coronavirus that causes COVID-19. The Vyriad IMMUNO-COV™ antibody test detects and quantifies neutralizing antibodies, the critical subset of antibodies that can block SARS-CoV-2 from infecting new cells.
IMMUNO-COV is distinct from most existing serology tests, which do not confirm the virus-neutralizing function of antibodies they detect. The SARS-CoV-2 virus uses its spike protein to infect healthy cells and spread throughout the body. The IMMUNO-COV antibody test uses a mimic virus, an innocuous virus that has been engineered to display the SARS-CoV-2 spike glycoprotein on its surface. It analyzes human blood serum to detect only the antibodies capable of ‘blocking’ the action of this spike glycoprotein, thus preventing the mimic virus from infecting new cells.
We believe IMMUNO-COV can address an important gap in the current antibody testing landscape, especially the need for a quantitative assay that can determine the:
- Neutralizing antibody levels in potential plasma donors and recipients participating in the national plasma therapy study.
- Relative potencies and effectiveness of SARS-CoV-2 vaccines in development, and the duration of immune response each vaccine elicits.
Vyriad’s IMMUNO-COV antibody test is conducted in CLIA-certified, high-complexity laboratories. There is no test kit. Physicians and other healthcare providers may order the test and submit blood samples for analysis to Vyriad or other participating labs.
Vyriad is the first company to run the test at its CLIA laboratory in Rochester, Minnesota. Vyriad does not engage in patient service and accepts blood samples only from referring physicians and laboratories. The test will become commercially available through major CLIA-certified testing labs beginning in early June.